胃肠道癌症患者化疗相关性味觉障碍的评估：一项初步研究。
Evaluation of Chemotherapy-induced Dysgeusia in Patients With Gastrointestinal Cancer: A Pilot Study.
机构信息
Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan;
Department of Surgery, Nakatsu Municipal Hospital, Oita, Japan.
出版信息
In Vivo. 2023 Jul-Aug;37(4):1894-1900. doi: 10.21873/invivo.13283.
BACKGROUND/AIM: Dysgeusia, one of the adverse effects of cancer chemotherapy, and anorexia due to taste disorder can significantly impair the quality of life of patients. However, an evaluation method for dysgeusia has not yet been established. The present prospective study aimed to utilize a combination of subjective and objective assessment methods to evaluate dysgeusia in patients with gastrointestinal cancer initiating chemotherapy, to determine chemotherapeutic drugs and regimens causing dysgeusia, and to assess whether dysgeusia was associated with zinc deficiency.
PATIENTS AND METHODS
A total of 21 patients with newly diagnosed gastrointestinal cancer were registered between August 2020 to March 2021. The following regimens were also included in the evaluation if the patients did not develop dysgeusia. A total 30 regimens were administered to the patients during the study period. A salt-impregnated test paper (Salsave) was used as a subjective assessment, and the chemotherapy-induced taste alteration scale was used as an objective assessment.
RESULTS
Based on physician interviews, dysgeusia was diagnosed in 8 of 21 patients (38%) treated with 8 of 30 regimens (27%). All regimens that resulted in dysgeusia contained platinum-based drugs. The patients who developed dysgeusia had higher controlling nutritional status scores at the start of chemotherapy compared to those who did not develop dysgeusia. In both subjective and objective assessments, the patients with dysgeusia performed significantly worse than those without dysgeusia. Six of the eight patients who developed dysgeusia were administered Novelzine, which did not improve the taste disorder despite the improvement of serum zinc levels.
CONCLUSION
The combined approach using subjective and objective taste assessment methods was useful in assessing chemotherapy-induced dysgeusia. Mechanisms other than hypozincemia should be considered as contributors to taste disorders caused by platinum-based drugs.
背景/目的：味觉障碍是癌症化疗的不良反应之一，味觉障碍引起的厌食会显著降低患者的生活质量。然而，目前尚未建立味觉障碍的评估方法。本前瞻性研究旨在利用主观和客观评估方法相结合，评估开始化疗的胃肠道癌症患者的味觉障碍，确定引起味觉障碍的化疗药物和方案，并评估味觉障碍是否与锌缺乏有关。
患者和方法
2020 年 8 月至 2021 年 3 月期间共登记了 21 例新诊断为胃肠道癌症的患者。如果患者没有出现味觉障碍，也将纳入评估的其他 30 种方案。在研究期间，共给患者使用了 30 种方案。盐浸渍测试纸（Salsave）用于主观评估，化疗引起的味觉改变量表用于客观评估。
结果
根据医生访谈，在接受 30 种方案中的 8 种（27%）治疗的 21 例患者中，有 8 例（38%）诊断为味觉障碍。所有引起味觉障碍的方案均含有铂类药物。发生味觉障碍的患者在化疗开始时的控营养状态评分高于未发生味觉障碍的患者。在主观和客观评估中，味觉障碍患者的表现明显劣于无味觉障碍的患者。在发生味觉障碍的 8 例患者中，有 6 例使用了 Novelzine，但尽管血清锌水平有所改善，味觉障碍仍未得到改善。
结论
使用主观和客观味觉评估方法相结合的方法，有助于评估化疗引起的味觉障碍。除了低锌血症外，还应考虑其他机制是导致铂类药物引起味觉障碍的原因。
Zotero 插件